C4671026
A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID-19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE
- Sex at Birth: Any
- Age: Child (Birth - 17)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II/III
- Conditions Being Studied: Other Respiratory and Intrathoracic Organs, COVID-19
Study Purpose
The purpose of the study is to find out if PF-07321332 (nirmatrelvir) co-packaged with ritonavir which is the study drug, helps treat non-hospitalized symptomatic children with COVID-19 who are at risk of their COVID-19 infection getting worse.
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00001690
- StudyID: 2022-0870
- ClinicalTrials.gov: NCT05261139
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422